KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Interest & Investment Income (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Interest & Investment Income data on record, last reported at $8.3 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 18.91% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $31.7 million, up 24.61%, while the annual FY2025 figure was $31.7 million, 24.61% up from the prior year.
  • Interest & Investment Income reached $8.3 million in Q4 2025 per ACAD's latest filing, up from $8.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $8.3 million in Q4 2025 and bottomed at $105000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $4.1 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 93.31% in 2021, then surged 3519.05% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $129000.0 in 2021, then skyrocketed by 2713.95% to $3.6 million in 2022, then skyrocketed by 31.1% to $4.8 million in 2023, then skyrocketed by 47.24% to $7.0 million in 2024, then increased by 18.91% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $8.3 million in Q4 2025, $8.2 million in Q3 2025, and $7.2 million in Q2 2025.